Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of tiragolumab plus atezolizumab in advanced solid tumors
jRCT2080224926Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tiragolumab and atezolizumab in Nonhematologic neoplasms, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities (DLTs), Safety and tolerability and 1 more. Started Oct 2019; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224926.